Breast and prostate cancers are the two predominant hormone-responsive tumours. The use of the antioestrogen tamoxifen in the treatment of breast cancer has evolved over the past 30 y from treatment for advanced breast cancer to prevention. Tamoxifen is currently the endocrine treatment of choice for advanced breast cancer and for adjuvant therapy in a broad spectrum of women whose primary tumours have functional oestrogen receptors. It has also been shown to reduce the incidence of breast cancer in high-risk women. Nonsteroidal antiandrogen therapy is used in the treatment of prostate cancer, but its role is still being de®ned. The clinical development of tamoxifen and that of the antiandrogens are reviewed and parallels are uncovered which provide insight into contemporary and future management of hormone-responsive prostate cancer. Prostate Cancer and Prostatic Diseases (2001) 4, 72±80.
Introduction
In the battle against advanced breast and prostate cancers, the use of endocrine manipulation has been accepted as ®rst-line treatment. Non-steroidal antiandrogen therapy is used in the treatment of prostate cancer, but its role is still being de®ned. This paper draws parallels between the clinical development of tamoxifen and that of the antiandrogens to provide insights into the potential role of the antiandrogens in the therapy of prostate cancer.
Tamoxifen in the treatment of breast cancer History and development
Regression of breast cancer as the result of endocrine therapy (ie oophorectomy) was ®rst described more than 100 years ago. 1 Ablative endocrine surgery became a mainstay in the palliative treatment of metastatic breast cancer, providing tumour control in approximately 30% of unselected women. It was not until the mid-1940s that a medical treatment, diethylstilbestrol (DES), was developed for postmenopausal women. 2 Development of non-steroidal antioestrogens, particularly tamoxifen, provided the next advance in hormonal therapy for breast cancer. Tamoxifen was developed initially in 1969 as a possible oral contraceptive, but preliminary trials in humans showed that the compound failed to work as an antifertility drug. 3 At about the same time, tamoxifen was shown to inhibit the growth of experimental hormone-dependent tumours. 4 The parallel discovery that the presence of oestrogen receptors in tumour tissue might predict the hormone responsiveness of advanced breast cancer 5 led to an evaluation of tamoxifen's ability to control tumour growth. Early trials with tamoxifen demonstrated that it was effective in the treatment of advanced breast cancer and had lower toxicity compared with other endocrine treatments. 6, 7 Oestrogen receptors reside in the nucleus of the cell. When bound by oestrogen the receptor molecules dimerise to form functional transcription factors, which are able to bind and activate promotor regions of oestrogen-activated genes. Tamoxifen is a type I antioestrogen that binds to the oestrogen receptor, blocking the binding of oestrogen and causing a change in the shape of the receptor complex, which prevents it functioning as a transcription factor. The oestrogen-activated genes that mediate breast cancer cell replication are thus inactivated.
In addition to oestrogen, adrenal androgens are thought to play a role in the development of breast cancer. Postmenopausal women with breast cancer have been found to have elevated plasma levels of adrenal androgens, 8 and these elevated levels have also been seen in women who later developed breast cancer. 9 
Study results
Tamoxifen, like other endocrine treatments, produced an objective response in approximately one-third of unselected women with advanced breast cancer. The observation of the predictive value of the oestrogen receptor for responsiveness to endocrine therapy in a subset of patients with breast cancers 5,10 prompted oestrogen receptor measurements in several clinical studies 11 ± 14 and provided the basis for a predictive test to select patients who would be more likely to respond to tamoxifen therapy. Results showed approximately 50 ± 60% of patients with oestrogen-receptor positive tumours responded to tamoxifen therapy. It was also demonstrated that, by measuring progesterone receptor levels, response to endocrine treatment could be further improved. 15 Women with oestrogen and progesterone receptor-positive tumours have a 70% probability of response to tamoxifen, whereas only 10% of women lacking these markers will respond. 16 Various studies compared tamoxifen treatment for advanced breast cancer with other types of endocrine therapy including oestrogens, 17 androgens, 18 progestins, 19,20 aminoglutethimide, 21,22 oophorectomy, 23,24 and adrenalectomy. 25 Generally, tamoxifen achieved response rates similar to those seen with other endocrine therapies but was associated with considerably less toxicity. The high objective response rate combined with low acute toxicity established tamoxifen as the treatment of choice for advanced relapsed metastatic breast cancer, particuarly in patients with oestrogen-receptor positive tumours and those with non-life-threatening visceral disease in which a rapid response is not essential.
Many multicentre trials of tamoxifen as adjuvant therapy were begun between 1975 and 1982. 13,26 ± 37 These trials varied considerably in design and in the dosage and duration of treatment. Generally, the results of these trials tended to point in the same direction: a reduction in the risk of relapse and death for patients receiving tamoxifen compared with those receiving placebo. By the early 1990s, 10-y data from adjuvant trials had become available. 38 ± 41 Analysis of the ®ndings indicated that tamoxifen 20 mg/day given as adjuvant therapy for 2 ± 5 y after primary treatment reduced the odds of recurrence and death each year for at least 10 y in most patient subsets. Speci®cally, this bene®t was observed in women with breast cancer that was oestrogen-receptor positive and also in women with breast cancer for whom no oestrogen receptor measurement was available; it was independent of age, menopausal status, or adjuvant tamoxifen treatment. Although there was some bene®t in patients with truly oestrogen-receptor negative tumours, the certainty of bene®t for these patients was less clear and remains a matter for research.
The optimal duration of adjuvant tamoxifen therapy remains controversial and continues to be the subject of evaluation in ongoing clinical studies. In the mid-1990s, analyses of several trials indicated that 5 y of adjuvant tamoxifen produced greater reductions in the risk of recurrence and death than did 1 or 2 y of treatment. 40, 42, 43 Results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-14; which evaluated 5 y vs 10 y of adjuvant tamoxifen treatment for early-stage breast cancer, indicated no advantage for continuation of tamoxifen beyond 5 y in women with node-negative, oestrogen-receptor positive breast cancers. 44 However, the results of a randomized trial conducted by the Eastern Cooperative Oncology Group (ECOG) 45 indicated that women with node-positive, oestrogen-receptor positive tumours experienced a longer time to relapse with tamoxifen therapy continued beyond 5 y (P 0.014), but the survival difference for this subgroup was not statistically signi®cant (P 0.81).
Breast cancer prevention
The ®nding of a decrease in contralateral breast cancer incidence after adjuvant tamoxifen therapy con®rmed a large amount of preclinical evidence that tamoxifen could block both the initiation and the progression of breast cancer in animal models. 4, 46 These data led to the theory that the drug might play a role in breast cancer prevention, and studies were undertaken to test this hypothesis.
Proving the value of tamoxifen in the prevention of breast cancer required very large (13 000 ± 20 000 subjects), randomized, placebo-controlled, double-blind clinical trials; three trials were started in Europe and North America. 47 The initial results of one trial, the Breast Cancer Prevention Trial, conducted by the NSABP, became available in 1998. 48 The study showed that tamoxifen (n 6681), when compared with placebo (n 6707), lowered the incidence of breast cancer by 49% (two-sided P`0.00001) in high-risk women (eg those aged 60 y; those aged 35 ± 59 y with a 5-year predicted risk for breast cancer of at least 1.66%; or those with a history of lobular carcinoma in situ). The risk decreased in women aged 49 y (44%), 50 ± 59 y (51%), and 60 y (55%). The incidence of breast cancer was reduced in women with a history of lobular carcinoma in situ or atypical hyperplasia. Tamoxifen also reduced the incidence of non-invasive breast cancer by 50%. Tamoxifen administration did not alter the average annual rate of ischaemic heart disease, but hip, radius (Colles'), and spine fractures were reduced. The rate of endometrial cancer increased in the tamoxifen group predominantly in women aged 50 y. All endometrial cancers in the tamoxifen group were stage I (localized disease); no endometrial cancer deaths have occurred in this group. No cases of liver cancer or increases in the incidences of colon, rectal, ovarian, or other tumours were observed in the tamoxifen group. The rates of stroke, pulmonary embolism, and deep vein thrombosis were elevated in the tamoxifen group; these occurred more frequently in women aged 50 y.
Although predominantly acting as an antioestrogen, tamoxifen acts as an oestrogen on the endometrium, bone, and cardiovascular system. Such oestrogenic action provides a protective effect against osteoporosis 49,50 and cardiovascular disease, 51, 53 but may stimulate endometrial cancer proliferation. 54 Adjuvant tamoxifen therapy has been associated with certain toxic effects. Although it is rare, the most important toxic effect is the development of endometrial cancer which, in large clinical trials, has been reported to occur at a rate that is 2 ± 3 times greater than that observed in untreated women. 55 ± 58 In this regard, it is important to put the risk : bene®t ratio of tamoxifen therapy into perspective. Tamoxifen therapy for women with breast cancer results in a survival advantage that far outweighs the risk of endometrial cancer. 59, 60 Healthy women who are using tamoxifen as a preventative measure for breast cancer may experience an increased incidence of endometrial cancer, and they must be carefully monitored, with periodic pelvic examinations, to decrease the probability of developing advanced uterine malignancy. Any abnormal uterine bleeding should be investigated.
Other toxic effects noted with tamoxifen include thromboembolic phenomena. In the Breast Cancer Prevention Trial, 48 three times as many cases of pulmonary embolism (17 vs six cases) and 1.5 times as many cases of deep venous thrombosis (30 vs 19 cases) were seen in tamoxifen-treated women than in those receiving placebo. These events were more frequent in women aged 50 y. Recent preliminary studies have suggested a protective action in breast cancer for a selective oestrogen modulator, raloxifene, initially developed for the prevention of osteoporosis. An initial analysis of the Multiple Outcomes of Raloxifene Evaluation (MORE) study, conducted in 7704 postmenopausal women with osteoporosis, suggests a b70% reduction in the incidence of breast cancer after treatment with raloxifene for 30 months (mean), compared with placebo. 61 Additionally, a meta-analysis of nine placebo-controlled trials (including MORE) involving around 12 000 patients showed a 58% reduction in relative breast cancer risk with raloxifene. 62 It should be noted that breast cancer development was not a primary outcome measure of MORE and the meta-analysis ®nd-ings were based on only 49 cases of breast cancer. Furthermore, in the only clinical trial with raloxifene in advanced breast cancer, women were treated with highdose raloxifene (300 mg/day). The authors concluded that further study of high-dose raloxifene as monotherapy for advanced breast cancer was probably unwarranted. 63 The ongoing Study of Tamoxifen and Raloxifene (STAR, also known as NSABP P-2) has been speci®cally designed to compare tamoxifen and raloxifene (given for 5 y) for breast cancer risk reduction in approximately 22 000 high-risk postmenopausal women. 64 In summary, based on evidence from clinical trials involving more than 35 000 women, tamoxifen has become the endocrine treatment of choice for advanced breast cancer and for adjuvant therapy in a broad spectrum of women whose primary tumours have functional oestrogen receptors. Tamoxifen has also been shown to reduce the incidence of breast cancer in women at increased risk for the disease.
Prostate cancer History and development
Hunter, Scottish anatomist and surgeon to St George's Hospital, ®rst suspected a relationship between testicular factors and prostate growth in the late 1700s. In the 1940s, it was the seminal work of Huggins and Hodges 65 that established the value of orchiectomy and oestrogens in the management of advanced prostate cancer. They showed that surgical castration or medical castration with oestrogen therapy produced a dramatic reduction in cancer mass and clinical remissions in 80% of patients with advanced metastatic disease. Huggins received the Nobel Prize in Medicine in 1966 for this work.
In the late 1960s, a large multicentre Veterans Administration study established that oestrogen (DES), although effective in advanced prostate cancer, had signi®cant cardiovascular and thromboembolic morbidity and mortality rates at a dose of 5 mg/day. 66 ± 69 Eventually other effective and less toxic ways of inhibiting androgenmediated action in metastatic prostate cancer were developed.
Luteinizing hormone-releasing hormone (LHRH) agonists were discovered by Schally and co-workers. 70 After causing a brief surge of LHRH and testosterone synthesis, the continued administration of an LHRH agonist resulted in a shutdown of the synthesis of luteinizing hormone in the pituitary gland which led to a cessation in the production of testosterone in the testes. 71 Development of LHRH agonists provided a medical alternative to DES without the unacceptable cardiovascular side effects. Clinical data established that LHRH agonist therapy was as effective as surgical castration 72 ± 74 or DES therapy. 75, 76 Two LHRH agonists are commonly used in the United States for the treatment of prostate cancer: leuprolide and goserelin. LHRH agonists cause impotence, hot¯ashes, and loss of libido, as do orchiectomy and oestrogens. Tumour¯are reactions may occur transiently but can be prevented by antiandrogens or by low-dose oestrogen treatment administered for several weeks. 77 Long-term androgen suppression with LHRH agonists or orchiectomy may result in loss of bone mineral density and put men at risk of osteoporotic fractures. 78, 79 Antiandrogen monotherapy was another approach evaluated in the hope of avoiding the side effects and psychological morbidity of orchiectomy and the cardiovascular side effects of oestrogen. These agents prevent the interaction of dihydrotestosterone (DHT) and testosterone with their receptors on the prostate cancer cell. Two steroidal antiandrogens evaluated in the 1980s, megestrol acetate 80 and cyproterone acetate, 81 are synthetic analogues of progesterone which bind to the progesterone receptor. These synthetic progestins block androgen action and also suppress androgen production; however, they also show variable levels of androgenic activity, 82 and are associated with elevated levels of prostate-speci®c antigen (PSA) in some patients. 83 Ketoconazole, an imidazole derivative useful as an antifungal agent, was also evaluated because of its ability to inhibit the synthesis of both testicular and adrenal androgens. 84 These drugs did not generate enthusiasm in the United States because of unacceptable side effects, 85, 86 and research interest shifted to non-steroidal antiandrogens, which lack the progestational side effects of their steroidal counterparts. In 1989,¯utamide was the ®rst nonsteroidal antiandrogen to receive Food and Drug Administration approval for use in combination with the LHRH agonist leuprolide. 87 Orchiectomy, DES, and LHRH agonists all act by inhibiting production of testosterone in the testes. However, the adrenal glands are believed to produce as much as 30% of the body's supply of androgens. 88 These androgens, which are closely related to testosterone, can also be converted to DHT and can promote prostate cancer growth. 89 ± 93 The concept of total androgen blockade using a combination of either bilateral orchiectomy or a LHRH agonist with an antiandrogen was postulated to provide greater ef®cacy by decreasing the overall effects of androgens (both from the testes and the adrenal glands) on prostate cancer growth.
Antiandrogens in combination therapy and monotherapy
The ®rst discussion of total androgen blockade is credited to Bracci et al. 94 Early non-randomized studies by Labrie et al 95 ± 101 led to the ®rst large, randomized, placebocontrolled trial of total androgen blockade by the National Cancer Institute (Intergroup 0036 study). 87 This study clearly demonstrated a survival advantage in patients with metastatic disease receiving total androgen blockade using daily injections of an LHRH agonist (leuprolide) plus¯utamide compared with an LHRH agonist alone, however, it also raised questions regarding the bene®t and role of this therapy. First, the overall survival bene®t of approximately 6 months is relatively modest and must be balanced against the added costs and the adverse reactions (gynaecomastia and diarrhoea) observed in patients taking leuprolide and¯utamide. Second, the therapeutic effect of non-steroidal antiandrogens may consist of the short-term blockade of the¯are reaction that accompanies LHRH agonist treatment, and the use of these agents may not be necessary over the long term. A Southwest Oncology Group Intergroup trial (SWOG-INT 0105) 102 was undertaken to con®rm the bene®ts of combined androgen blockade (CAB) reported in the Intergroup 0036 study. The principal difference from the earlier trial was that bilateral orchiectomy replaced therapy with leuprolide. There was a small, statistically insigni®cant difference between the two groups (CAB vs orchiectomy) in overall survival.
Bicalutamide was the second non-steroidal antiandrogen marketed in the United States and has become the most widely prescribed antiandrogen. The compound has a long plasma elimination half-life, compatible with oncedaily dosing, and has a higher binding af®nity to the androgen receptor than¯utamide. 103 Clinical trials with bicalutamide began in 1987. A 50 mg daily dose of bicalutamide was initially evaluated as monotherapy in Phase II and III trials. 104, 105 In a combined analysis of three comparative studies involving 1196 patients with advanced disease, bicalutamide monotherapy at 50 mg/ day was associated with statistically signi®cantly shorter survival when compared with surgical or medical castration (25 vs 28 months, respectively). 106 However, when combined with an LHRH agonist, bicalutamide 50 mg/ day demonstrated at least equivalent survival and was better tolerated than a corresponding¯utamide (250 mg three times daily) combination regimen. 107, 108 A meta-analysis of CAB trials has recently been published, 109 including all CAB vs castration trials. However, this made no clear distinction between non-steroidal antiandrogens and steroidal antiandrogens in its conclusions. Steroidal antiandrogens (cyproterone acetate) in addition to castration actually had a detrimental effect on overall survival, while non-steroidal antiandrogens showed a small survival bene®t. 109, 110 None of the overview analyses have looked at duration of therapy. Recently Sarosdy et al 111 suggested that prolonged antiandrogen use as part of CAB did result in a signi®cant prolongation of overall survival. This supports the principle that a patient will not bene®t from antiandrogen therapy if he is no longer able to take the right dose, eg due to tolerability or compliance.
Because no limits on tolerability were reached with bicalutamide 50 mg/day and the PSA response to bicalutamide is dose-related, subsequent trials investigated a 150 mg daily dosage. Bicalutamide 150 mg/day was compared with surgical or medical castration in two large, randomized, Phase III trials involving previously untreated patients with locally advanced or metastatic disease. 112 In the subset of patients (n 480) with locally advanced, non-metastatic disease (T3-4 Nx M0), the analysis of the pooled data from several trials demonstrated that survival for those treated with bicalutamide 150 mg/ day was no different from survival in the group treated with castration (HR 0.93; 95% CI 0.66, 1.31). 113 In the subgroup (n 808) with metastatic disease, survival with bicalutamide 150 mg monotherapy was slightly but signi®cantly shorter (6 weeks) than that seen with castration. Patients treated with bicalutamide monotherapy had signi®cantly better palliation (subjective response) and maintained sexual interest and physical capacity to a signi®cantly greater extent than did those patients treated by castration. 114 In these trials of bicalutamide 150 mg monotherapy versus castration, a subgroup was assessed for effects of long-term (b5 y) treatment on their bone mineral density. Bone mineral density (BMD) was assessed in 29 patients (21 patients received bicalutamide, eight patients castration) with no bone metastases. After a median follow-up of 5.5 y with treatment uninterrupted, BMD for bicalutamide-treated patients was as good as BMD in agematched controls, while BMD in castrated patients was lower. One of the seven castrated patients had BMD at a level with a considerable risk of fracture. 113 There is evidence that second-line treatment with bicalutamide may provide a bene®t after failure of primary treatment with¯utamide. For example, Scher et al 115 observed that 10 of 26 patients who progressed on utamide treatment had a b50% decline in serum PSA levels after initiation of bicalutamide 200 mg/day as second-line therapy. Similarly, Joyce et al 116 found that six of 14 patients who progressed on¯utamide treatment demonstrated bene®t with bicalutamide 150 mg/day. Unlike oestrogen receptors in breast cancer, androgen receptors frequently undergo mutation during endocrine treatment. 117, 118 It is not known whether progression after successful antiandrogen treatment is related to mutation, but the observed responsiveness to bicalutamide in patients who progress on¯utamide treatment supports in vitro evidence that different antiandrogens interact differently with wild-type and/or mutant androgen receptors. 119 In some patients, withdrawal of antiandrogen treatment actually enhances tumour responsiveness, suggesting agonist activity at androgen receptors; this phenomenon has most commonly been observed for utamide but has also been reported for bicalutamide and steroidal antiandrogens, as well as for tamoxifen in breast cancer. 120 ± 122 Data on the responsiveness of patients who progress on bicalutamide to alternative antiandrogen treatments are scant; for example, no study has examined the responsiveness to¯utamide. 115 Controlled, adequately powered clinical trials in de®ned populations are required to determine the impact of second-line antiandrogen treatment on survival. Furthermore, the mechanisms responsible for the sensitivity to bicalutamide after progression on¯utamide treatment deserve further study.
A third non-steroidal antiandrogen, nilutamide, recently became commercially available in the United States. Both¯utamide and bicalutamide are indicated for use in combination with an LHRH agonist; nilutamide is indicated in combination with bilateral orchiectomy. A discussion of nilutamide is beyond the scope of this paper.
Antiandrogens as adjuvant therapy
With the widespread use of prostate speci®c antigen (PSA) testing, the number of patients with prostate cancer diagnosed at an early stage is increasing. However, despite earlier detection, many men still have cancer that is not con®ned to the prostate, and, therefore, cure is not possible with surgery alone. 123 This observation underscores the need for an effective, systemic adjuvant treatment for men with early-stage disease. The proven bene®t of adjuvant antioestrogen therapy in women with early breast cancer raises the possibility that adjuvant antiandrogen therapy might have a similar bene®t for men with early prostate cancer.
Early controlled trials evaluating adjuvant therapy in prostate cancer demonstrated promising progression-free survival bene®ts for regimens including estramustine 124 goserelin plus cyproterone acetate, 125 goserelin alone, 126 and an LHRH agonist plus¯utamide. 127 The trial of goserelin plus cyproterone acetate also showed an overall survival bene®t. 125 Two controlled trials have considered non-steroidal antiandrogen monotherapy as adjuvant therapy. Wirth et al 128 reported that, in 365 men, time to recurrence of disease could be delayed by¯utamide adjuvant to radical prostatectomy. In 1995, a large clinical trial was initiated to compare bicalutamide 150 mg/day with placebo in patients with localized or locally advanced prostate cancer (stage T1b-T4, N0-Nx, M0). Patients were randomized to treatment with bicalutamide or placebo as adjuvant to standard care (either prostatectomy, radiation or watchful waiting). Enrolment of 8113 patients was completed in 1998. 129 At a median follow-up of 3 years, bicalutamide signi®cantly reduced the risk of disease progression in these patients. 130 Longer follow-up is needed to determine whether adjuvant antiandrogen therapy in early prostate cancer will have a bene®t in terms of survival.
Prostate cancer prevention
Given the impact of antioestrogen therapy with tamoxifen on breast cancer prevention, it seems logical to investigate the potential role of antiandrogen therapy in prostate cancer prevention. The enzyme 5a-reductase is responsible for conversion of testosterone to DHT, which has a greater af®nity than testosterone for the androgen receptor and is thought to modulate prostatic growth. 130 Finasteride, a 5a-reductase inhibitor, is approved for treatment of benign prostatic hypertrophy. 131 Finasteride may hold promise as a chemopreventive agent and is being evaluated in the Prostate Cancer Prevention Trial, which has already enrolled more than 18 000 men to receive either active treatment or placebo daily for 7 y. 132 It is anticipated that results of this trial will be available in 2004. Of concern, however, are the disappointing preliminary ®ndings with ®nasteride as a chemopreventative agent. 133 In 27 patients with an elevated PSA level but not prostate cancer, treatment with ®nas-teride for 12 months decreased the PSA level by 48% but had no signi®cant effect on the extent of hyperplastic epithelium in the peripheral zone.
Similar to identifying healthy women at risk of breast cancer, it will be important to be able to identify healthy men at increased risk of prostate cancer. Risk factors that will have to be taken into account include age, race, having a ®rst-degree family member with a history of prostate cancer, having had a biopsy of the prostate gland (regardless of outcome), elevated PSA level, and/or high-grade prostatic intraepithelial neoplasia (PIN). The spectrum of histopathological changes referred to as high-grade PIN is the most likely precursor lesion of invasive prostate cancer. 134 Clinicopathological studies suggest that PIN predates prostate cancer by 10 y or more. 135, 136 High-grade PIN is currently the best marker available to identify men with an increased risk of prostate cancer diagnosis. It is probably not a good surrogate endpoint with which to replace prostate cancer diagnosis for a prevention trial. Androgen deprivation therapy decreases the prevalence and extent of high-grade PIN, implying that the dysplastic prostatic epithelium is androgen-dependent. 137 Interestingly, the preliminary study of ®nasteride as a chemopreventative agent demonstrates that blockade of 5a-reductase appears to have less effect on high-grade PIN than other forms of androgen suppression. 133 Of the antiandrogens available, bicalutamide is an attractive candidate as a chemopreventive agent, as its side effects are more tolerable than those of other forms of androgen deprivation therapy.
For breast cancer, determinations of the cellular concentrations of oestrogen and progesterone-receptors in the tumour are clinically useful in predicting prognosis and outcome to therapeutic endocrine manipulations. Androgens mediate the growth of prostate cancer cells. Intracellular action of androgens is mediated by the androgen receptor, which is a key element of the androgen signal transduction cascade and a target of endocrine therapy for prostate cancer. Therefore, the qualitative (point mutations) and quantitative (receptor ampli®cation) alterations of androgen receptor expression in prostate cancer and their possible implications for tumour progression and treatment are of great interest. There have been variable results regarding the clinical signi®cance of cells expressing androgen receptors in prostate cancer. Consequently, the predictive value of androgen receptor content of prostate cancers in patient outcome is controversial. 138 ± 140 Indeed, the molecular mechanisms that contribute to hormone refractoriness and progression of prostate cancers are poorly understood. 141 Therefore, much additional experimental work will be necessary to de®ne the genetic and molecular steps associated with progression of prostate cancer, as well as to translate these biological ®ndings into clinical applications.
Summary
The use of endocrine manipulation in the treatment of both breast and prostate cancers has been shaped by the increased understanding of the pathophysiological roles of oestrogen and androgen, respectively, in promoting tumour growth. In particular, combined hormonal blockade, which both reduces androgen and oestrogen production and prevents the cellular activity of these hormones, has produced improved survival rates over monotherapy or medical castration in both diseases. Antioestrogen therapy for breast cancer using tamoxifen has progressed from use in advanced metastatic disease through adjuvant use to chemoprevention of primary disease. The biological similarity between breast and prostate cancer has contributed to parallel development strategies for antiandrogen treatment for metastatic prostate cancer initially, with adjuvant therapy under investigation, and perhaps to be followed by prevention. The most notable distinction between antioestrogen therapy for breast cancer and antiandrogen therapy for prostate cancer is the lack of a clinical correlation between the ef®cacy of antiandrogen treatment and androgen receptor status. A further limitation to the comparison of these two diseases is the high mutation rate of androgen receptors during endocrine treatment which is not seen in oestrogen receptors.
The particular characteristics of the individual endocrine agents have also been a factor in shaping the roles of endocrine manipulation in these two cancers, and in this regard, tamoxifen and the antiandrogens share several common features (Table 1 ). The success of tamoxifen in the treatment of breast cancer is reason to be cautiously optimistic that similar success may be achieved with antiandrogen therapy in prostate cancer. In combination with an LHRH agonist, non-steroidal antiandrogens demonstrated improved survival compared with an LHRH agonist alone 87, 108 Adjuvant therapy in addition to standard care
Reduced the odds of recurrence and death each year for at least 10 y in most patient subsets with localized disease 38 ± 41 Ongoing trials are investigating role as neoadjuvant and adjuvant therapy. Evidence is accumulating that use of hormonal therapy in addition to standard care for localized and locally advanced disease will prolong survival 125, 143 Prevention Lowered the risk of breast cancer by 49% in high-risk women 48 Androgen deprivation therapy decreases the prevalence and extent of high-grade PIN 
